Pharmacokinetics of intravenous telavancin in healthy subjects with varying degrees of renal impairment

PURPOSE: We evaluated the effect of renal impairment (RI) on the pharmacokinetics of telavancin and hydroxypropylbetadex (excipient in the telavancin drug product). METHODS: Adults with normal, mild, moderate or severe RI or end-stage renal disease (ESRD) receiving haemodialysis were included in two...

Descripción completa

Detalles Bibliográficos
Autores principales: Worboys, Philip D., Wong, Shekman L., Barriere, Steven L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2015
Materias:
Pharmacokinetics and Disposition
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4430595/
https://www.ncbi.nlm.nih.gov/pubmed/25939708
http://dx.doi.org/10.1007/s00228-015-1847-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4430595/
https://www.ncbi.nlm.nih.gov/pubmed/25939708
http://dx.doi.org/10.1007/s00228-015-1847-6

Ejemplares similares